samedan logo

 
 
spacer
home > pmps > spring 2019 > maintaining security and sterility
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Maintaining Security and Sterility

Many of today’s newer pharmaceutical formulas require more stringent moisture, light, or oxygen protection. Formulas are also becoming more potent, leading to demand for metered dosing in small tube diameters for low (yet powerful) fill volumes. Here, small high-barrier tubes offer attractive user-friendliness and can diminish over-packaging by eliminating the need for secondary packaging like pouches and barrier blisters. They can also provide increased safety through simplicity: the fewer ‘moving parts’ a package has, the lower the likelihood of accidental misuse by end-users.

The Tube Packaging Market

Looking at the larger picture, it is interesting to note that, according to MarketsandMarkets, the worldwide tube packaging market is projected to grow at a compound annual growth rate of 6.9% during the forecast period of 2016 to 2021, approaching US $9.3 billion by 2021 (1).

The tube packaging market is gaining momentum due to factors that include overall growth in the flexible packaging sector and increased demand for small size packs for cosmetic and personal care products. Additional factors driving the market are advancements in tube technologies and, as previously noted, heightened demand for enhanced barrier properties to protect sensitive pharmaceutical products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Martina Christiansen is Head of Sales and Marketing Pharmaceutical at Hoffmann Neopac, a global provider of high-quality tube packaging for a broad array of industries and applications.
spacer
Martina Christiansen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BRIM Biotechnology Receives FDA Agreement on Phase 3 Clinical Trial Design for BRM421, BRIM’s Lead Candidate for Dry Eye Disease, at End of Phase 2 Meeting

Taipei, Taiwan, 1st November 2022 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRIM," TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. BRIM will submit the Phase 3 study protocol to the FDA in Q4 2022.
More info >>

White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement